RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath®MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more t ...